Risk of malignancy associated with biologic agents in pediatric rheumatic disease.

摘要: Purpose of review The Food and Drug Administration report an increased rate malignancy among children treated with tumor necrosis factor inhibitors is worrisome. These concerns prompted rigorous studies the incidence associated juvenile idiopathic arthritis, both without treatment specific therapeutic agents. This article reviews risk biologic agents for arthritis childhood-onset systemic lupus erythematosus. Recent findings Several demonstrated background although impact medication use on was less clear. Similarly, erythematosus likely risk, unknown. Summary diagnoses are malignancy, irrespective use. Further to estimate risks pediatric rheumatic diseases their treatments needed.